SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration

Economic evaluations in wet age-related macular degeneration (ARMD) is hampered as often utility values for solely one eye are used, mostly the better-seeing eye (BSE). Moreover, frequently chosen methods rely on patient values and/or disease specific measures, while economic evaluations prefer gene...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2017-02, Vol.12 (2), p.e0169816
Main Authors: Visser, Martijn S, Amarakoon, Sankha, Missotten, Tom, Timman, Reinier, Busschbach, Jan J
Format: Article
Language:English
Subjects:
Acuity
Age
Age related diseases
Aged
Aged, 80 and over
Analysis
Biology and Life Sciences
Clinical trials
Computer and Information Sciences
Diabetes
Diabetic retinopathy
Elderly
Equivalence
Eye
Female
Health
Health aspects
Health economics
Health Status
Humans
Macular degeneration
Macular Degeneration - diagnosis
Male
Medicine and Health Sciences
Morbidity
Patients
Physiological aspects
Psychiatry
Psychometrics
Psychotherapy
Quality of Life
Quality-Adjusted Life Years
Questionnaires
Social Sciences
Studies
Utilities
Visual acuity
Visual Acuity - physiology
Wet Macular Degeneration - diagnosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c725t-314950dda7e1d559cdba75947378ea2239d53ac14565986f3854250e2d5c8d383
cites cdi_FETCH-LOGICAL-c725t-314950dda7e1d559cdba75947378ea2239d53ac14565986f3854250e2d5c8d383
container_end_page
container_issue 2
container_start_page e0169816
container_title PloS one
container_volume 12
creator Visser, Martijn S
Amarakoon, Sankha
Missotten, Tom
Timman, Reinier
Busschbach, Jan J
description Economic evaluations in wet age-related macular degeneration (ARMD) is hampered as often utility values for solely one eye are used, mostly the better-seeing eye (BSE). Moreover, frequently chosen methods rely on patient values and/or disease specific measures, while economic evaluations prefer generic quality of life (QoL) measures based on societal preferences. The generic QoL utility instrument EQ-5D has shown to be insensitive for differences in visual acuity. The aim of this study was therefore to provide societal utility values, using the generic SF-6D, for health states acknowledging both BSE and worse-seeing eye (WSE). SF-6D utility values of 191 ARMD patients (≥65 years) with 153 follow-up measures at 1 year were used to fill health states defined by the combination of BSE and WSE using Snellen equivalents; no visual loss (≥20/40), mild-moderate (20/200) and severe (≤20/200). QoL utilities were estimated for the SF-6D, ranging from 0.740 for ARMD patients without visual loss to 0.684 for patients with a combination of mild-moderate visual loss in their BSE and severe visual loss in their WSE. Societal utility values are provided for ARMD patients using the generic QoL instrument SF-6D for visual acuity health states based on both BSE and WSE. The range of the values is smaller than previous elicited utilities with the disease-specific VisQoL. Besides, the utility values are placed on a more realistic position on the utility scale, and SF-6D utility values avoid the problem associated with the interpretation of disease-specific utility values.
doi_str_mv 10.1371/journal.pone.0169816
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1870938030</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A482147739</galeid><doaj_id>oai_doaj_org_article_e1799213d9224e4ca0effb902b96b393</doaj_id><sourcerecordid>A482147739</sourcerecordid><originalsourceid>FETCH-LOGICAL-c725t-314950dda7e1d559cdba75947378ea2239d53ac14565986f3854250e2d5c8d383</originalsourceid><addsrcrecordid>eNqNk81u1DAUhSMEoqXwBggsISFYZPBPnMQbpKpQqFSpEgW2lhPfZFx57KnttPRheFc8P606qIsqi1jOd45vzvUtitcEzwhryKcLPwWn7GzpHcwwqUVL6ifFPhGMljXF7Om99V7xIsYLjDlr6_p5sUdbSnkjxH7x9_y4rL-gKRlr0g26UnaCiAYfUJoD6iAlCCVSTqNrHyKUEcC4EcENrKE5KJvmKCaVsqxTETTybq09d2AtOASXk8m24BIyDi1VMnkZ0bXJOjVCGcBmsUYL1U9WBaRhBAchc969LJ4NykZ4tX0fFL-Ov_48-l6enn07OTo8LfuG8lQyUgmOtVYNEM256HWnGi6qhjUtKEqZ0JypnlS85qKtB9byinIMVPO-1axlB8Xbje_S-ii3yUZJ2gYL1mKGM3GyIbRXF3IZzEKFG-mVkesNH0apQjK9BQkkJ0sJ04LSCqpeYRiGTmDaibpjgmWvz9vTpm4Bus95BGV3THe_ODOXo7-SnFFS1atyP2wNgr_M_UpyYWKf41YO_LSuu2lZzWv8GJRwjiuxcn33H_pwEFtqzD2Vxg0-l9ivTOVh1eb6mib_40Exe4DKj4aF6fONHUze3xF83BFkJsGfNKopRnly_uPx7NnvXfb9PXZzXaO30-p2xV2w2oB98DEGGO76QbBcDdxtGnI1cHI7cFn25n4v70S3E8b-AbQ5JgE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1870938030</pqid></control><display><type>article</type><title>SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Visser, Martijn S ; Amarakoon, Sankha ; Missotten, Tom ; Timman, Reinier ; Busschbach, Jan J</creator><contributor>Abe, Toshiaki</contributor><creatorcontrib>Visser, Martijn S ; Amarakoon, Sankha ; Missotten, Tom ; Timman, Reinier ; Busschbach, Jan J ; Abe, Toshiaki</creatorcontrib><description>Economic evaluations in wet age-related macular degeneration (ARMD) is hampered as often utility values for solely one eye are used, mostly the better-seeing eye (BSE). Moreover, frequently chosen methods rely on patient values and/or disease specific measures, while economic evaluations prefer generic quality of life (QoL) measures based on societal preferences. The generic QoL utility instrument EQ-5D has shown to be insensitive for differences in visual acuity. The aim of this study was therefore to provide societal utility values, using the generic SF-6D, for health states acknowledging both BSE and worse-seeing eye (WSE). SF-6D utility values of 191 ARMD patients (≥65 years) with 153 follow-up measures at 1 year were used to fill health states defined by the combination of BSE and WSE using Snellen equivalents; no visual loss (≥20/40), mild-moderate (&lt;20/40-&gt;20/200) and severe (≤20/200). QoL utilities were estimated for the SF-6D, ranging from 0.740 for ARMD patients without visual loss to 0.684 for patients with a combination of mild-moderate visual loss in their BSE and severe visual loss in their WSE. Societal utility values are provided for ARMD patients using the generic QoL instrument SF-6D for visual acuity health states based on both BSE and WSE. The range of the values is smaller than previous elicited utilities with the disease-specific VisQoL. Besides, the utility values are placed on a more realistic position on the utility scale, and SF-6D utility values avoid the problem associated with the interpretation of disease-specific utility values.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0169816</identifier><identifier>PMID: 28225799</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Acuity ; Age ; Age related diseases ; Aged ; Aged, 80 and over ; Analysis ; Biology and Life Sciences ; Clinical trials ; Computer and Information Sciences ; Diabetes ; Diabetic retinopathy ; Elderly ; Equivalence ; Eye ; Female ; Health ; Health aspects ; Health economics ; Health Status ; Humans ; Macular degeneration ; Macular Degeneration - diagnosis ; Male ; Medicine and Health Sciences ; Morbidity ; Patients ; Physiological aspects ; Psychiatry ; Psychometrics ; Psychotherapy ; Quality of Life ; Quality-Adjusted Life Years ; Questionnaires ; Social Sciences ; Studies ; Utilities ; Visual acuity ; Visual Acuity - physiology ; Wet Macular Degeneration - diagnosis</subject><ispartof>PloS one, 2017-02, Vol.12 (2), p.e0169816</ispartof><rights>COPYRIGHT 2017 Public Library of Science</rights><rights>2017 Visser et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2017 Visser et al 2017 Visser et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c725t-314950dda7e1d559cdba75947378ea2239d53ac14565986f3854250e2d5c8d383</citedby><cites>FETCH-LOGICAL-c725t-314950dda7e1d559cdba75947378ea2239d53ac14565986f3854250e2d5c8d383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1870938030/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1870938030?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28225799$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Abe, Toshiaki</contributor><creatorcontrib>Visser, Martijn S</creatorcontrib><creatorcontrib>Amarakoon, Sankha</creatorcontrib><creatorcontrib>Missotten, Tom</creatorcontrib><creatorcontrib>Timman, Reinier</creatorcontrib><creatorcontrib>Busschbach, Jan J</creatorcontrib><title>SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Economic evaluations in wet age-related macular degeneration (ARMD) is hampered as often utility values for solely one eye are used, mostly the better-seeing eye (BSE). Moreover, frequently chosen methods rely on patient values and/or disease specific measures, while economic evaluations prefer generic quality of life (QoL) measures based on societal preferences. The generic QoL utility instrument EQ-5D has shown to be insensitive for differences in visual acuity. The aim of this study was therefore to provide societal utility values, using the generic SF-6D, for health states acknowledging both BSE and worse-seeing eye (WSE). SF-6D utility values of 191 ARMD patients (≥65 years) with 153 follow-up measures at 1 year were used to fill health states defined by the combination of BSE and WSE using Snellen equivalents; no visual loss (≥20/40), mild-moderate (&lt;20/40-&gt;20/200) and severe (≤20/200). QoL utilities were estimated for the SF-6D, ranging from 0.740 for ARMD patients without visual loss to 0.684 for patients with a combination of mild-moderate visual loss in their BSE and severe visual loss in their WSE. Societal utility values are provided for ARMD patients using the generic QoL instrument SF-6D for visual acuity health states based on both BSE and WSE. The range of the values is smaller than previous elicited utilities with the disease-specific VisQoL. Besides, the utility values are placed on a more realistic position on the utility scale, and SF-6D utility values avoid the problem associated with the interpretation of disease-specific utility values.</description><subject>Acuity</subject><subject>Age</subject><subject>Age related diseases</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis</subject><subject>Biology and Life Sciences</subject><subject>Clinical trials</subject><subject>Computer and Information Sciences</subject><subject>Diabetes</subject><subject>Diabetic retinopathy</subject><subject>Elderly</subject><subject>Equivalence</subject><subject>Eye</subject><subject>Female</subject><subject>Health</subject><subject>Health aspects</subject><subject>Health economics</subject><subject>Health Status</subject><subject>Humans</subject><subject>Macular degeneration</subject><subject>Macular Degeneration - diagnosis</subject><subject>Male</subject><subject>Medicine and Health Sciences</subject><subject>Morbidity</subject><subject>Patients</subject><subject>Physiological aspects</subject><subject>Psychiatry</subject><subject>Psychometrics</subject><subject>Psychotherapy</subject><subject>Quality of Life</subject><subject>Quality-Adjusted Life Years</subject><subject>Questionnaires</subject><subject>Social Sciences</subject><subject>Studies</subject><subject>Utilities</subject><subject>Visual acuity</subject><subject>Visual Acuity - physiology</subject><subject>Wet Macular Degeneration - diagnosis</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNk81u1DAUhSMEoqXwBggsISFYZPBPnMQbpKpQqFSpEgW2lhPfZFx57KnttPRheFc8P606qIsqi1jOd45vzvUtitcEzwhryKcLPwWn7GzpHcwwqUVL6ifFPhGMljXF7Om99V7xIsYLjDlr6_p5sUdbSnkjxH7x9_y4rL-gKRlr0g26UnaCiAYfUJoD6iAlCCVSTqNrHyKUEcC4EcENrKE5KJvmKCaVsqxTETTybq09d2AtOASXk8m24BIyDi1VMnkZ0bXJOjVCGcBmsUYL1U9WBaRhBAchc969LJ4NykZ4tX0fFL-Ov_48-l6enn07OTo8LfuG8lQyUgmOtVYNEM256HWnGi6qhjUtKEqZ0JypnlS85qKtB9byinIMVPO-1axlB8Xbje_S-ii3yUZJ2gYL1mKGM3GyIbRXF3IZzEKFG-mVkesNH0apQjK9BQkkJ0sJ04LSCqpeYRiGTmDaibpjgmWvz9vTpm4Bus95BGV3THe_ODOXo7-SnFFS1atyP2wNgr_M_UpyYWKf41YO_LSuu2lZzWv8GJRwjiuxcn33H_pwEFtqzD2Vxg0-l9ivTOVh1eb6mib_40Exe4DKj4aF6fONHUze3xF83BFkJsGfNKopRnly_uPx7NnvXfb9PXZzXaO30-p2xV2w2oB98DEGGO76QbBcDdxtGnI1cHI7cFn25n4v70S3E8b-AbQ5JgE</recordid><startdate>20170222</startdate><enddate>20170222</enddate><creator>Visser, Martijn S</creator><creator>Amarakoon, Sankha</creator><creator>Missotten, Tom</creator><creator>Timman, Reinier</creator><creator>Busschbach, Jan J</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20170222</creationdate><title>SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration</title><author>Visser, Martijn S ; Amarakoon, Sankha ; Missotten, Tom ; Timman, Reinier ; Busschbach, Jan J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c725t-314950dda7e1d559cdba75947378ea2239d53ac14565986f3854250e2d5c8d383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acuity</topic><topic>Age</topic><topic>Age related diseases</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis</topic><topic>Biology and Life Sciences</topic><topic>Clinical trials</topic><topic>Computer and Information Sciences</topic><topic>Diabetes</topic><topic>Diabetic retinopathy</topic><topic>Elderly</topic><topic>Equivalence</topic><topic>Eye</topic><topic>Female</topic><topic>Health</topic><topic>Health aspects</topic><topic>Health economics</topic><topic>Health Status</topic><topic>Humans</topic><topic>Macular degeneration</topic><topic>Macular Degeneration - diagnosis</topic><topic>Male</topic><topic>Medicine and Health Sciences</topic><topic>Morbidity</topic><topic>Patients</topic><topic>Physiological aspects</topic><topic>Psychiatry</topic><topic>Psychometrics</topic><topic>Psychotherapy</topic><topic>Quality of Life</topic><topic>Quality-Adjusted Life Years</topic><topic>Questionnaires</topic><topic>Social Sciences</topic><topic>Studies</topic><topic>Utilities</topic><topic>Visual acuity</topic><topic>Visual Acuity - physiology</topic><topic>Wet Macular Degeneration - diagnosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Visser, Martijn S</creatorcontrib><creatorcontrib>Amarakoon, Sankha</creatorcontrib><creatorcontrib>Missotten, Tom</creatorcontrib><creatorcontrib>Timman, Reinier</creatorcontrib><creatorcontrib>Busschbach, Jan J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Opposing Viewpoints Resource Center</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Visser, Martijn S</au><au>Amarakoon, Sankha</au><au>Missotten, Tom</au><au>Timman, Reinier</au><au>Busschbach, Jan J</au><au>Abe, Toshiaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2017-02-22</date><risdate>2017</risdate><volume>12</volume><issue>2</issue><spage>e0169816</spage><pages>e0169816-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Economic evaluations in wet age-related macular degeneration (ARMD) is hampered as often utility values for solely one eye are used, mostly the better-seeing eye (BSE). Moreover, frequently chosen methods rely on patient values and/or disease specific measures, while economic evaluations prefer generic quality of life (QoL) measures based on societal preferences. The generic QoL utility instrument EQ-5D has shown to be insensitive for differences in visual acuity. The aim of this study was therefore to provide societal utility values, using the generic SF-6D, for health states acknowledging both BSE and worse-seeing eye (WSE). SF-6D utility values of 191 ARMD patients (≥65 years) with 153 follow-up measures at 1 year were used to fill health states defined by the combination of BSE and WSE using Snellen equivalents; no visual loss (≥20/40), mild-moderate (&lt;20/40-&gt;20/200) and severe (≤20/200). QoL utilities were estimated for the SF-6D, ranging from 0.740 for ARMD patients without visual loss to 0.684 for patients with a combination of mild-moderate visual loss in their BSE and severe visual loss in their WSE. Societal utility values are provided for ARMD patients using the generic QoL instrument SF-6D for visual acuity health states based on both BSE and WSE. The range of the values is smaller than previous elicited utilities with the disease-specific VisQoL. Besides, the utility values are placed on a more realistic position on the utility scale, and SF-6D utility values avoid the problem associated with the interpretation of disease-specific utility values.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>28225799</pmid><doi>10.1371/journal.pone.0169816</doi><tpages>e0169816</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2017-02, Vol.12 (2), p.e0169816
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_1870938030
source Publicly Available Content Database; PubMed Central
subjects Acuity
Age
Age related diseases
Aged
Aged, 80 and over
Analysis
Biology and Life Sciences
Clinical trials
Computer and Information Sciences
Diabetes
Diabetic retinopathy
Elderly
Equivalence
Eye
Female
Health
Health aspects
Health economics
Health Status
Humans
Macular degeneration
Macular Degeneration - diagnosis
Male
Medicine and Health Sciences
Morbidity
Patients
Physiological aspects
Psychiatry
Psychometrics
Psychotherapy
Quality of Life
Quality-Adjusted Life Years
Questionnaires
Social Sciences
Studies
Utilities
Visual acuity
Visual Acuity - physiology
Wet Macular Degeneration - diagnosis
title SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T06%3A32%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SF-6D%20utility%20values%20for%20the%20better-%20and%20worse-seeing%20eye%20for%20health%20states%20based%20on%20the%20Snellen%20equivalent%20in%20patients%20with%20age-related%20macular%20degeneration&rft.jtitle=PloS%20one&rft.au=Visser,%20Martijn%20S&rft.date=2017-02-22&rft.volume=12&rft.issue=2&rft.spage=e0169816&rft.pages=e0169816-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0169816&rft_dat=%3Cgale_plos_%3EA482147739%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c725t-314950dda7e1d559cdba75947378ea2239d53ac14565986f3854250e2d5c8d383%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1870938030&rft_id=info:pmid/28225799&rft_galeid=A482147739&rfr_iscdi=true